Anika Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview

Anika Therapeutics

07/05/2025 13:38

Anika Therapeutics Inc ANIK.OQ ANIK.O is expected to show a fall in quarterly revenue when it reports  results on May 9 for the period ending March 31 2025

The Bedford Massachusetts-based  company is expected to report a 30.7% decrease in revenue to $28.067 million from $40.52 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Anika Therapeutics Inc is for a loss of 14 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 1,866.7% in the last three months. ​

Wall Street's median 12-month price target for Anika Therapeutics Inc is $21.00​, above​ its last closing price of $14.08. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.51
-0.29
-1.50
Missed
-408.5
Sep. 30 2024
-0.04
-0.01
-0.25
Missed
-1,566.7
Jun. 30 2024
0.07
0.05
-0.01
Missed
-121.4​
Mar. 31 2024
-0.21
-0.19
-0.31
Missed
-66.1
​​Dec. 31 2023
-0.26
-4.30
Missed
-1,532.9
Sep. 30 2023
-0.38
-0.37
-0.45
Missed
-20.5​
Jun. 30 2023
-0.27
-0.27
-0.19
Beat
29.6
Mar. 31 2023
-0.33
-0.30
-0.47
Missed
-56.7

This summary was machine generated May 7 at 12:38 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)